Ads
related to: darzalex pomalyst dexamethasone regimen- DARZALEX® Side Effects
Find Information About Side Effects
Patients May Experience
- Cost Support Options
Learn About Potential Cost Support
Options Through Janssen CarePath
- Read Patient Stories
Learn About the Treatment Journey
From Real Patients & Caregivers
- About DARZALEX®
Learn About a Treatment Method and
How DARZALEX® Works
- Important Safety Info
Learn About Important Safety
Information for DARZALEX®
- Questions for Your Doctor
Find a List Of Questions for You to
Ask Your Healthcare Provider
- DARZALEX® Side Effects
Search results
Results From The WOW.Com Content Network
Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38 , [ 7 ] which is overexpressed in multiple myeloma cells. [ 8 ]
It was approved for use in the United States in May 2020. [2] [7] [8]Efficacy of daratumumab and hyaluronidase-fihji (monotherapy) was evaluated in the COLUMBA trial (NCT03277105), an open-label non-inferiority trial randomizing 263 participants to daratumumab and hyaluronidase-fihj and 259 to intravenous daratumumab (daratumumab IV). [2]
AbbVie's combination improved the median progression-free survival period to 9.9 months, compared with 5.8 months for a combination of Bristol-Myers Squibb's Pomalyst and dexamethasone, but the ...
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology , many regimens combine several chemotherapy drugs in combination chemotherapy .
GSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to data from a late ...
For premium support please call: 800-290-4726 more ways to reach us
In July 2021, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj in combination with pomalidomide and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor. [36]
The trial assessed Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BVd) versus Johnson & Johnson’s (NYSE:JNJ) Darzalex (daratumumab) in combination with ...
Ads
related to: darzalex pomalyst dexamethasone regimen